The world is desperate for weight-loss drugs. But Big Pharma can’t advertise them

CNN Business

Jul 21

London — The temperature was 92 degrees Fahrenheit. The sweat, profuse. And I was walking toward an exhibition about the “obesity experience” on London’s bustling riverside funded by a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2653274378"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653274378\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653274378?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-21 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653274378","market":"us","top_or_hot":-1,"title":"The world is desperate for weight-loss drugs. But Big Pharma can’t advertise them","media":"CNN Business","content":"<div>\n<p>London — \n\n\n            The temperature was 92 degrees Fahrenheit. The sweat, profuse. And I was walking toward an exhibition about the “obesity experience” on London’s bustling riverside funded by a ...</p>\n\n<a href=\"https://edition.cnn.com/2026/07/21/business/glp1-weight-loss-drug-advertising\">Source Link</a>\n\n</div>\n","source":"cnn_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The world is desperate for weight-loss drugs. But Big Pharma can’t advertise them</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe world is desperate for weight-loss drugs. But Big Pharma can’t advertise them\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-21 19:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://edition.cnn.com/2026/07/21/business/glp1-weight-loss-drug-advertising><strong>CNN Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>London — \n\n\n            The temperature was 92 degrees Fahrenheit. The sweat, profuse. And I was walking toward an exhibition about the “obesity experience” on London’s bustling riverside funded by a ...</p>\n\n<a href=\"https://edition.cnn.com/2026/07/21/business/glp1-weight-loss-drug-advertising\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756325.SGD","symbol_name":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","start_time":0,"source_url":"https://edition.cnn.com/2026/07/21/business/glp1-weight-loss-drug-advertising","article_id":"2653274378","we_media_id":null,"thumbnails":[],"rights":{"source":"cnn_highlight","url":"https://edition.cnn.com/2026/07/21/business/glp1-weight-loss-drug-advertising","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2653274378","pubTimestamp":1784631960,"columns":[],"sourceInfo":{"source_id":"cnn_highlight","name":"CNN Business"},"weMediaInfo":null,"summary":"The temperature was 92 degrees Fahrenheit. The sweat, profuse. And I was walking toward an exhibition about the “obesity experience” on London’s bustling riverside funded by a $220 billion pharmaceutical company.It was day two of two. In a few hours’ time, the exhibition, designed as a maze, would be gone. And so too would be my chance to see, up close, the promotional gymnastics of a booming weight-loss drug industry bound by strict laws around what it can – and absolutely cannot – say to the British public.When I appeared at the mouth of the maze, a green T-shirted man explained that he was from Danish drugmaker Novo Nordisk. The exhibition, he said, represents the many stops, starts and setbacks people find when trying to lose weight — it can sort of feel like getting lost in a maze.Yet, in many countries, including Britain, companies can promote their brands via so-called “disea","collect":0,"end_time":0,"defaultTopTitle":"cnn.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4585":"ETF&股票定投概念","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","NVOH":"Novo Nordisk A/S B Shares ADRhedged","NVO":"诺和诺德","BK4588":"碎股","BK4532":"文艺复兴科技持仓","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","BGIA":"Baillie Gifford International Alpha ETF","BK4599":"减肥药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4007":"制药","NVOX":"2倍做多NVO ETF-Defiance","PPH":"VanEck Pharmaceutical ETF","OZEM":"Roundhill GLP-1 & Weight Loss ETF","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC"},"translate_title":"世界急需减肥药。但大型制药公司不能为它们做广告","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JDOC":0.79,"BGIA":0.88,"NVOX":0.6,"PPH":0.6,"THNR":0.6,"NVOH":0.6,"NVO":0.88,"OZEM":0.6},"content_text":"London — \n\n\n            The temperature was 92 degrees Fahrenheit. The sweat, profuse. And I was walking toward an exhibition about the “obesity experience” on London’s bustling riverside funded by a $220 billion pharmaceutical company.\n    \n\n            It was day two of two. In a few hours’ time, the exhibition, designed as a maze, would be gone. And so too would be my chance to see, up close, the promotional gymnastics of a booming weight-loss drug industry bound by strict laws around what it can – and absolutely cannot – say to the British public.\n    \n\n            Heatwave be damned, I was going.\n    \n\n            When I appeared at the mouth of the maze, a green T-shirted man explained that he was from Danish drugmaker Novo Nordisk. The exhibition, he said, represents the many stops, starts and setbacks people find when trying to lose weight — it can sort of feel like getting lost in a maze.\n    \n\n\n\n\n\n\n\n\n\n\n\n\n\nA \"maze\" exhibition on obesity funded by Novo Nordisk in London, July 2026.\nCNN\n\n\n\n\n\n            I asked what Novo Nordisk did or made specifically.\n    \n\n            “I don’t know,” he replied.\n    \n\n            I asked again.\n    \n\n            “Ok, I do know. I’m just not allowed to tell you.”\n    \n\n        The American Exception\n\n\n            Novo Nordisk is the maker of Ozempic and Wegovy, GLP-1 medications approved for diabetes control and weight loss, respectively. Like all pharmaceutical companies and pharmacies in Britain, it is banned from advertising medications to the public that can only be prescribed by a doctor. And so, in a country where the market for weight loss drugs is extremely competitive, they must get creative.\n    \n\n            In the United States, it’s a very different picture.\n    \n\n            “It’s everywhere,” said Jesse Dresser, a partner at Frier Levitt, a New Jersey-based law firm specializing in healthcare and life sciences. “It’s every television program … every time you go on the internet … you wind up invariably seeing (ads) for drugs.”\n    \n\n\n\n\n\n\n\n\nA commercial for GLP-1 drugs during the Super Bowl LX broadcast on television screens at a bar in California, United States in February 2026.\n\nJill Connelly/Bloomberg/Getty Images\n\n\n\n\n\n            But — and I say this with love to American readers — that is not normal. In fact, the vast majority of countries around the world ban ads for prescription-only medications to the public. The US and New Zealand are the only exceptions.\n    \n\n            The First Amendment to the US Constitution restricts the American government from regulating most kinds of speech, and helps to explain the US’ outliter status, Dresser said. In 1997, the US Food and Drug Administration also relaxed rules around drug ads on TV and radio, paving the way for Big Pharma’s omnipresence in American life today – despite recent government efforts to restrain the practice.\n    \n\n            Yet, in many countries, including Britain, companies can promote their brands via so-called “disease awareness campaigns,” where they can provide information about a health condition but under no circumstances push a specific medication.\n    \n\n\n\n\n\n\n\n\nAn information board on obesity in Novo Nordisk's maze exhibition in London, July 2026\n\nCNN\n\n\n\n\n\n            A spokesperson for Novo Nordisk told CNN that it aimed to encourage people to understand obesity as a complex, chronic health condition through its July disease awareness campaign.\n    \n\n            “Obesity is often misunderstood and associated with stigma, and we believe more open, informed conversations can help improve understanding of the realities people face,” the spokesperson said in a statement.\n    \n\n            Washington is also taking a stricter stance on Big Pharma advertising than in years past. Health Secretary Robert F. Kennedy Jr. has spoken openly of his wish to ban direct-to-consumer ads, arguing that they are fueling over-consumption of prescription medications.\n    \n\n            Though an outright ban is unlikely – it would meet stiff legal challenges from the industry – President Donald Trump has directed federal agencies to more stringently enforce existing regulations. His administration is also hoping to introduce new rules requiring companies to make lengthier disclosures of drugs’ side effects.\n    \n\n\n\n\n\n\n\n\nUS Health and Human Services Secretary Robert F. Kennedy Jr. is interviewed on Fox News outside of the White House West Wing in September 2025 in Washington, DC.\n\nWin McNamee/Getty Images\n\n\n\n\n\n            Geoff Meacham, global head of healthcare at Citi, told CNN that drug advertising in the US has ramped up over the past 10 to 15 years.\n    \n\n            Then, ads were mostly for drugs targeted at a very broad consumer market, like statins to lower cholesterol, or Botox, he said.\n    \n\n            “But then they started to advertise cancer drugs – and now it’s (for) everything.”\n    \n\n        Public complaints\n\n\n            The Danish drugmaker is far from unique.\n    \n\n            Its American rival Eli Lilly, the maker of GLP-1s Mounjaro and Zepbound, recently ran its own campaign in London. A few weeks ago, I spotted a poster on the city’s transit network reading: “Obesity is a complex disease.” It directed viewers to an Eli Lilly website with a questionnaire intended to “empower” an “informed discussion” with a healthcare provider about their weight.\n    \n\n            Britain’s Advertising Standards Authority told CNN that it normally receives only one two complaints about any given ad, but it has received over 100 complaints from members of the public about Eli Lilly’s ad campaign. Jessica Tye, regulatory projects manager at the ASA, said a chunk of those complaints argued that Eli Lilly should have made its commercial interests more explicit.\n    \n\n            Tye said the regulator is assessing the complaints but has not decided whether to launch an investigation into the ad.\n    \n\n            In France, however, both GLP-1 giants have already fallen afoul of advertising rules. Earlier this year, the country’s pharmaceutical regulator announced fines of roughly €1.8 million euros ($2.1 million) for Novo Nordisk and €110,000 ($126,000) for Eli Lilly over public campaigns it considered to be indirect promotion(s)” of prescription-only drugs.\n    \n\n            The ads were “likely to mislead audiences in a context marked by extensive media coverage and increasing misuse of (GLP-1s), particularly for weight loss purposes with aesthetic goals,” the regulator ANSM said in a statement.\n    \n\n            Novo Nordisk said it was “exploring all possible legal avenues to challenge”  ANSM’s decision. “These campaigns – which are no longer being broadcast – were part of best practices for prevention and awareness, designed to ensure the safety of the patient care pathway and to share reliable information with patients,” a spokesperson said in a statement.\n    \n\n            Eli Lilly did not respond to CNN’s request for comment. The company said in a statement to French newspaper Le Monde in May that it believed its campaign was “in line with the framework applicable to communications relating to human health.”\n    \n\n        A ‘gray area’\n\n\n            The bulk of weight-loss ads come not from the makers of GLP-1s but the raft of online pharmacies distributing them.\n    \n\n            Tye, at Britain’s ASA, said some of these pharmacies have strayed into a “gray area” between a disease awareness campaign and flagrant prescription drug promotion, such as using images that heavily imply a specific medication.\n    \n\n            “There’s a huge opportunity for businesses in this sector… so it’s perhaps not surprising that we’ve seen huge numbers of these ads and that we have seen quite a lot creeping into that gray area,” she told CNN.\n    \n\n            Despite their relative permissiveness, health agencies in the US are cracking down on online pharmacies’ promotion of GLP-1s – specifically ads for their copycat, or “compounded,” versions that were needed to fill previous supply shortages of name-brand products.\n    \n\n            The US FDA has sent dozens of warning letters to telehealth companies this year over misleading ads for compounded GLP-1s, many of which implied the drugs were FDA-approved. Compounded drugs are not FDA approved, and they are not mass-produced to the same specification, but customized – perhaps adding a novel ingredient or altering the drug’s form.\n    \n\n\n\n\n\n\n\n\nAn information board on the outside of Novo Nordisk's obesity exhibition in London, July 2026.\n\nCNN\n\n\n\n\n\n            Back in London, as I entered the maze, I overheard Green T-shirt’s colleagues reassure him that he had responded correctly to my questions (bushes aren’t very soundproof). As I wound my way through, information boards and TV screens cited statistics on obesity in Britain and featured interviews with people saying how difficult they found losing weight.\n    \n\n            One board, in small print, read: “This experience does not promote any specific treatment or product.”\n    \n\n            Everywhere was Novo Nordisk’s logo. Nowhere were its drugs.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}